Buparlisib (BKM120) is an orally administered ATP-competitive inhibitor of the PI3K pathway, under development by Novartis.
Definition from NCI Drug Dictionary
PI3K inhibitor BKM120 (buparlisib): An orally bioavailable specific oral inhibitor of the pan-class I phosphatidylinositol 3-kinase (PI3K) family of lipid kinases with potential antineoplastic activity. PI3K inhibitor BKM120 specifically inhibits class I PIK3 in the PI3K/AKT kinase (or protein kinase B) signaling pathway in an ATP-competitive manner, thereby inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate and activation of the PI3K signaling pathway. This may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.
Information at manufacturer's website: http://www.novartisoncology.us/research/pipeline/bkm120.jsp
Current Clinical Trials Relevant to GIST